J
Jeffrey Laurence
Researcher at Cornell University
Publications - 253
Citations - 7040
Jeffrey Laurence is an academic researcher from Cornell University. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Virus. The author has an hindex of 41, co-authored 242 publications receiving 5999 citations. Previous affiliations of Jeffrey Laurence include University of California, San Diego & Oklahoma Medical Research Foundation.
Papers
More filters
Journal ArticleDOI
Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases.
Cynthia M. Magro,J. Justin Mulvey,David A. Berlin,Gerard J. Nuovo,Steven P. Salvatore,Joanna Harp,Amelia Baxter-Stoltzfus,Jeffrey Laurence +7 more
TL;DR: At least a subset of sustained, severe COVID-19 may define a type of catastrophic microvascular injury syndrome mediated by activation of complement pathways and an associated procoagulant state, and could suggest targets for specific intervention.
Journal ArticleDOI
Thrombotic Thrombocytopenic Purpura and Sporadic Hemolytic-Uremic Syndrome Plasmas Induce Apoptosis in Restricted Lineages of Human Microvascular Endothelial Cells
Debashis Mitra,Eric A. Jaffe,Babette B. Weksler,Katherine A. Hajjar,Carl Soderland,Jeffrey Laurence +5 more
TL;DR: These phenomena support the pathophysiologic significance of microvascular EC apoptosis in TTP, extend it to a related disorder (sporadic HUS), and suggest consideration of apoptosis inhibitors in the experimental therapeutics of these syndromes.
Journal ArticleDOI
Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen.
TL;DR: The COP-BLAM therapy is an easily administered outpatient program capable of inducing a high frequency of durable complete remissions in advanced diffuse histiocytic lymphoma, a malignancy formerly considered to have a poor prognosis.
Journal ArticleDOI
HIV Envelope gp120-mediated Regulation of Osteoclastogenesis via Receptor Activator of Nuclear Factor κB Ligand (RANKL) Secretion and Its Modulation by Certain HIV Protease Inhibitors through Interferon-γ/RANKL Cross-talk
TL;DR: These findings offer a molecular basis for the acceleration of bone resorption by certain PIs and provide the first example of clinically useful drugs that can interfere with the cross-talk between RANKL and interferon-γ via the proteasome, and suggest a novel therapeutic approach to HIV osteopenia through modulation of these two molecules.
Journal ArticleDOI
Superantigen implicated in dependence of HIV-1 replication in T cells on TCR V β expression
TL;DR: It is indicated that a superantigen targets a subpopulation of CD4+ cells for viral replication, and Vβ12+ T cells were not deleted in AIDS patients, raising the possibility that a variety of mechanisms contribute to T-cell depletion.